Zealand Pharma A/S Sustainability Profile
Zealand Pharma A/S, a leading biotechnology company headquartered in Denmark (DK), is renowned for its innovative approach to peptide-based therapeutics. Founded in 1998, the company has made significant strides in the biopharmaceutical industry, focusing on the development of novel treatments for diabetes, obesity, and gastrointestinal disorders. With a strong presence in Europe and North America, Zealand Pharma is committed to advancing its core products, which include unique peptide therapies that offer targeted solutions for complex health issues. The company has achieved notable milestones, including strategic partnerships and successful clinical trials, solidifying its position as a key player in the global biopharmaceutical market. Zealand Pharma's dedication to scientific excellence and patient-centric solutions continues to drive its growth and impact in the healthcare landscape.
DitchCarbon Score
How does Zealand Pharma A/S's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zealand Pharma A/S's score of 30 is lower than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zealand Pharma A/S's reported carbon emissions
In 2021, Zealand Pharma A/S reported total carbon emissions of approximately 23,144,000 kg CO2e, a decrease from about 31,130,000 kg CO2e in 2020. These figures encompass Scope 1 and 2 emissions, indicating the company's direct and indirect greenhouse gas emissions from energy use. Zealand Pharma is committed to achieving net-zero emissions, with this commitment officially recognised as "Committed" as of May 29, 2025. While specific near-term and long-term reduction targets have not been disclosed, the company is actively working towards its climate goals within the pharmaceuticals, biotechnology, and life sciences sector. The emissions data is not cascaded from any parent organisation, ensuring that the reported figures are solely from Zealand Pharma A/S. The company continues to align its strategies with industry standards for climate action, reflecting a proactive approach to sustainability and environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | |
|---|---|---|
| Scope 1 | - | - |
| Scope 2 | - | - |
| Scope 3 | - | - |
How Carbon Intensive is Zealand Pharma A/S's Industry?
How Carbon Intensive is Zealand Pharma A/S's Location?
Zealand Pharma A/S's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Zealand Pharma A/S has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Zealand Pharma A/S's sustainability data and climate commitments